---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264371323.md"
description: "Novo Nordisk's European stock fell over 4% as the company's third-quarter performance was below expectations, and it lowered its full-year sales growth forecast"
datetime: "2025-11-05T08:03:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264371323.md)
  - [en](https://longbridge.com/en/news/264371323.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264371323.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264371323.md) | [繁體中文](https://longbridge.com/zh-HK/news/264371323.md)


# 

Novo Nordisk's European stocks fell over 4% as the company's third-quarter performance was below expectations, and it lowered its full-year sales growth forecast

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast](https://longbridge.com/en/news/280570178.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [Novo Nordisk A/S Approves Board Changes](https://longbridge.com/en/news/280694583.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/en/news/280694679.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)